Neural Stem Cells not checked

Clarion Cells, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke”In the company’s words, NCT04631406 on ClinicalTrials.gov
Tested for
Ischemic Stroke
Main trialPhase 1/2
“Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.”In the company’s words, NCT04631406 on ClinicalTrials.gov

Other drugs for Ischemic Stroke

All 45 drugs for Ischemic Stroke

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 12 Aug 2025 A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Neural Stem Cells

Following is part of Solo: you see every change to Neural Stem Cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in